Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) CFO Sells $22,066.02 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky sold 6,939 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $3.18, for a total transaction of $22,066.02. Following the sale, the chief financial officer now owns 111,811 shares of the company’s stock, valued at approximately $355,558.98. This represents a 5.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

MaxCyte Price Performance

Shares of MXCT stock opened at $3.09 on Friday. MaxCyte, Inc. has a 1-year low of $2.76 and a 1-year high of $5.26. The business’s fifty day moving average price is $4.04 and its 200 day moving average price is $3.93. The firm has a market capitalization of $327.63 million, a PE ratio of -9.09 and a beta of 1.35.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. BTIG Research set a $6.00 target price on MaxCyte and gave the company a “buy” rating in a research note on Wednesday, March 12th.

Hedge Funds Weigh In On MaxCyte

A number of large investors have recently made changes to their positions in MXCT. Cadian Capital Management LP grew its position in MaxCyte by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock worth $38,873,000 after buying an additional 1,155,476 shares during the period. Mirabella Financial Services LLP acquired a new stake in shares of MaxCyte in the 4th quarter worth approximately $15,392,000. River Global Investors LLP increased its stake in MaxCyte by 57.7% in the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock valued at $13,494,000 after purchasing an additional 1,190,630 shares in the last quarter. Mudita Advisors LLP raised its holdings in MaxCyte by 2.2% during the fourth quarter. Mudita Advisors LLP now owns 3,223,407 shares of the company’s stock worth $13,409,000 after purchasing an additional 69,966 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in MaxCyte by 2.0% during the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after purchasing an additional 47,960 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.